

---

*Please use only the valid version of the package insert provided with the kit.*

*This kit is intended for Research Use Only. Not for use in diagnostic procedures.*

## 1 INTENDED USE

This ELISA (enzyme-linked immunosorbent assay) kit is intended for determination of human Fetuin-A, also known as alpha-2-HS glycoprotein (AHSG), in serum, plasma, cell culture supernatant, tissue extraction and urine.

## 2 ASSAY PRINCIPLE

This ELISA is designed, developed and produced for the quantitative measurement of human Fetuin-A in serum samples. The assay utilizes the two-site “sandwich” technique with two selected goat anti-human Fetuin-A polyclonal antibodies that bind to different epitopes of human Fetuin-A.

Assay standards, controls and prediluted serum samples containing human Fetuin-A is added to microtiter wells of microplate that was coated with a high affinity polyclonal goat anti-human Fetuin-A antibody. After the first incubation period, the antibody on the wall of microtiter well captures human Fetuin-A in the sample and unbound proteins in each microtiter well is washed away. Then a horseradish peroxidase (HRP) conjugated polyclonal anti-human Fetuin-A antibody is added to each microtiter well and a “sandwich” of “capture antibody - human Fetuin-A - HRP conjugated tracer antibody” is formed. The unbound tracer antibody is removed in the subsequent washing step. HRP conjugated tracer antibody bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the Fetuin-A on the wall of the microtiter well is directly proportional to the amount of Fetuin-A in the sample. A standard curve is generated by plotting the absorbance versus the respective human Fetuin-A concentration for each standard on point-to-point or cubical scales. The concentration of human Fetuin-A in test samples is determined directly from this standard curve.

## 3 REAGENTS: PREPARATION AND STORAGE

This test kit must be stored at 2 – 8°C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable at 2 – 8°C until this expiration date.

**Prior to use, allow all reagents to come to room temperature.** Regents from different kit lot numbers should not be combined or interchanged.

### 1. Fetuin-A Antibody Coated Microplate

One microplate with 12 x eight strips (96 wells total) coated with antibody to human Fetuin-A.

The plate is framed and sealed in a foil Ziploc bag with a desiccant.

This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

**2. Fetuin-A Tracer Antibody**

One vial containing 0.6 mL concentrated horseradish peroxidase (HRP) conjugated anti-human Fetuin-A tracer antibody in a stabilized protein matrix.

*This reagent must be diluted with Tracer Antibody Diluent before use.*

This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

**3. Tracer Antibody Diluent**

One vial containing 12 mL ready to use Trizma Hydrochloride based buffer as supplied.

*It should be only used for tracer antibody dilution according to the assay procedures.*

This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

**4. Fetuin-A Assay Buffer Concentrate**

One vial containing 11 mL of concentrated phosphate buffered saline based assay buffer with bovine serum albumin added.

*This concentrated assay buffer must be diluted 1:10 with distilled or deionized water (11 mL concentrate plus 99 mL distilled water) before use.*

This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

**5. ELISA Wash Concentrate**

One bottle contains 20 mL of 30-fold concentrate.

*Before use the contents must be diluted with 580 mL of distilled water and mix well.*

Upon dilution this yields a working wash solution containing a surfactant in phosphate buffered saline with a non-azide preservative. The diluted solution should be stored at room temperature and is stable until the expiration date on the kit box.

**6. ELISA HRP Substrate Solution**

One bottle contains 12 mL of tetramethylbenzidine (TMB) with hydrogen peroxide.

This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

**7. ELISA Stop Solution**

One bottle contains 12 mL of 0.5 M sulfuric acid.

This reagent should be stored at 2 – 8°C or room temperature and is stable until the expiration date on the kit box.

**8. Fetuin-A Standards**

Five vials each contains human Fetuin-A in a liquid bovine serum based matrix with a non-azide preservative.

**Refer to vial for exact concentration for each standard.**

All the standards should be stored at -20°C or below after the first use with up to 3 freeze cycles.

**9. Fetuin-A Controls**

Two vials each contains human Fetuin-A in a liquid bovine serum based matrix with a non azide preservative.

**Refer to vials for exact concentration range for each control.**

Both controls should be store at -20°C or below after the first use with up to 3 freeze cycles.

#### 4 SAFETY PRECAUTIONS

This kit is intended for Research Use Only. Not for use in diagnostic procedures.

Source material from which reagents of bovine serum was derived in the contiguous 48 United States. It was obtained only from donor health animals maintained under veterinary supervision and found free of contagious diseases.

Wear gloves while performing this assay and handle these reagents as if they are potential infectious.

Avoid contact with reagents containing TMB, hydrogen peroxide, or sulfuric acid. TMB may cause irritation to skin and mucous membranes and cause an allergic skin reaction. TMB is a suspected carcinogen. Sulfuric acid may cause severe irritation on contact with skin. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes.

Use Good Laboratory Practices.

#### 5 MATERIALS REQUIRED BUT NOT PROVIDED

1. Precision single channel pipettes capable of delivering 10 µL, 25 µL, 100 µL, and 1000 µL.
2. Repeating dispenser suitable for delivering 100 µL.
3. Disposable pipette tips suitable for above volume dispensing.
4. Disposable 12 x 75 mm or 13 x 100 glass or plastic tubes.
5. Disposable plastic 100 mL and 1000 mL bottle with caps.
6. Aluminum foil.
7. Deionized or distilled water.
8. Plastic microtiter well cover or polyethylene film.
9. ELISA multichannel wash bottle or automatic (semi-automatic) washing system.
10. Spectrophotometric microplate reader capable of reading absorbance at 450 nm.

#### 6 SPECIMEN COLLECTION

Only 10 µL of **human serum or plasma** is required for human Fetuin-A measurement.

No special preparation of individual is necessary prior to specimen collection. Whole blood should be collected and must be allowed to clot for minimum 30 minutes at room temperature before the serum is separated by centrifugation (850 – 1500 x g for 10 minutes). The serum should be separated from the clot within three hours of blood collection and transferred to a clean test tube.

Serum samples may be stored at –20°C or below until measurement. Avoid repeated more than three times freezing and thawing of specimen.

**Twenty four hour urine sample** is recommended to be used for the determination of urine Fetuin-A concentration.

Spot urine from the second morning urination may be used if strenuous physical activity shortly before sample collection has been ruled out and polyuric renal dysfunction is not present. Intra-individual day-to-day fluctuations in the concentration of urine proteins caused by diuresis may be reduced by relating to the urinary creatinine concentration.

For **cell culture supernatant, tissue extracts**, one should serial dilute test sample and measure multiple diluted samples for a more accurate Fetuin-A test result.

## 7 ASSAY PROCEDURE

### 7.1 Sample Preparation

Serum or plasma sample need to be diluted 1:10,000 with assay buffer before being measured.

- (1) Label 2 test tubes (12x75 mm) with 1A and 1B.
- (2) Add 1 mL of assay buffer to each tube (both 1A and 1B).
- (3) Pipet 10 µL of serum or plasma sample to tube 1A and mix well (1:100 dilution).
- (4) Pipet 10 µL of diluted sample from 1A to tube 1B mix well (1:10,000 dilution).

*Note: It is recommended to use a precision/calibrated pipette and careful technique to perform the dilution in order to get precise results! We recommend using Eppendorf Repeat Pipette with 12.5 mL combitip for adding 1 ml assay buffer and don't use 50 mL combitip.*

Urine sample need to be diluted 1:100 with assay buffer before being measured.

- (1) Label 1 test tubes (12x75 mm) with 1.
- (2) Add 1 mL of assay buffer to each tube.
- (3) Pipet 10 µL of urine sample to tube 1 and mix well (1:100 dilution).

*Note: If a higher than standard level 5 of Fetuin-A test result is obtained, a further dilution of urine sample (e.g. 1:500) should be measured for reporting a more accurate test result.*

### 7.2 Reagent Preparation

- (1) Prior to use allow all reagents to come to room temperature. Regents from different kit lot numbers should not be combined or interchanged.
- (2) Fetuin-A Assay Buffer Concentrate and ELISA Wash Concentrate must be diluted to working solution prior use. Please see REAGENTS section for details.

### 7.3 Assay Procedure

- (1) Place a sufficient number of antibody coated microwell strips in a holder to run human Fetuin-A standards, controls and unknown samples in duplicate.
- (2) Test Configuration

ROW	STRIP 1	STRIP 2	STRIP 3
A	STD 1	STD 5	SAMPLE 2
B	STD 1	STD 5	SAMPLE 2
C	STD 2	C 1	SAMPLE 3
D	STD 2	C 1	SAMPLE 3
E	STD 3	C 2	
F	STD 3	C 2	
G	STD 4	SAMPLE 1	
H	STD 4	SAMPLE 1	

- (3) Add 25 µL of standards, controls and 1:10,000 diluted samples into the designated microwell. *Note: if urine sample is used, 1:100 diluted urine sample should be used.*
- (4) Add 100 µL of assay buffer to each well.
- (5) Mix gently and cover the plate with one plate sealer and also with aluminum foil to avoid exposure to light.
- (6) Incubate the plate at room temperature for 2 hours.
- (7) Prepare Tracer Antibody Working Solution by 1:21 fold dilution of the Fetuin-A Tracer Antibody with the Tracer Antibody Diluent.  
For each strip, it is required to mix 1 mL of Tracer Antibody Diluent with 50 µL of Fetuin-A Tracer Antibody in a clean test tube.
- (8) Remove the aluminum foil and the plate sealer. Aspirate the contents of each well. Wash each well 5 times by dispensing 350 µL of working wash solution into each well and then completely aspirating the contents.  
Alternatively, an automated microplate washer can be used.
- (9) Add 100 µL of above diluted tracer antibody working solution to each of the wells.
- (10) Cover the plate with one plate sealer and also with aluminum foil to avoid exposure to light.
- (11) Incubate the plate at room temperature for 30 minutes.
- (12) Remove the aluminum foil and the plate sealer. Aspirate the contents of each well. Wash each well 5 times by dispensing 350 µL of working wash solution into each well and then completely aspirating the contents.  
Alternatively, an automated microplate washer can be used.
- (13) Add 100 µL of ELISA HRP Substrate into each of the wells.
- (14) Cover the plate with aluminum foil to avoid exposure to light.
- (15) Incubate the plate at room temperature for 20 minutes
- (16) Remove the aluminum foil. Add 100 µL of ELISA Stop Solution into each of the wells. Mix gently.
- (17) Read the absorbance at 450 nm within 10 minutes in a microplate reader

NOTE: to reduce the background, one can set the instrument to dual wavelength measurement at 450 nm with background wavelength correction set at 595 nm or 620 nm or 630 nm.

---

## 8 PROCEDURAL NOTES

1. It is recommended that all standards, controls and unknown samples be assayed in duplicate. The average absorbance reading of each duplicate should be used for data reduction and the calculation of results.
2. Keep light sensitive reagents in the original amber bottles.
3. Store any unused antibody coated strips in the foil Ziploc bag with desiccant to protect from moisture.
4. Careful technique and use of properly calibrated pipetting devices are necessary to ensure reproducibility of the test.
5. Incubation times or temperatures other than those stated in this insert may affect the results.
6. Avoid air bubbles in the microwell as this could result in lower binding efficiency and higher CV% of duplicate reading
7. All reagents should be mix gently and thoroughly prior use. Avoid foaming.

## 9 INTERPRETATION OF RESULTS

1. Calculate the average absorbance for each pair of duplicate test results.
2. Subtract the average absorbance of the STD 1 (0 ng/mL) from the average absorbance of all other readings to obtain corrected absorbance.
3. The standard curve is generated by the corrected absorbance of all standard levels on the ordinate against the standard concentration on the abscissa using point-to-point or log-log paper. Appropriate computer assisted data reduction programs may also be used for the calculation of results.

The human serum or plasma Fetuin-A concentrations for the controls and 1:10,000 diluted samples are read directly from the standard curve using their respective corrected absorbance. If log-log graphic paper or computer assisted data reduction program utilizing logarithmic transformation are used, sample having corrected absorbance between the 1 ng/mL standard and the next highest standard should be calculated by the formula:


$$\text{Value of unknown} = \frac{\text{Corrected absorbance (unknown)}}{\text{Corrected Absorbance (2}^{\text{nd}} \text{ STD)}} \times \text{Value of the 2}^{\text{nd}} \text{ STD}$$

## 10 EXAMPLE DATA AND STANDARD CURVE

A typical absorbance data and the resulting standard curve from human Fetuin-A ELISA are represented. **This curve should not be used in lieu of standard curve run with each assay.**

Well I.D.	OD 450 nm Absorbance			Results ng/mL
	Readings	Average	Corrected	
0 ng/mL	0.097 0.099	0.098	0.000	
12.5 ng/mL	0.173 0.185	0.179	0.081	
38 ng/mL	0.364 0.379	0.371	0.273	
120 ng/mL	0.876 0.949	0.913	0.815	
370 ng/mL	2.298 2.325	2.312	2.214	
Control 1	0.471 0.498	0.484	0.386	55.1 ng/mL
Control 2	1.697 1.700	1.690	1.592	258.9 ng/mL

Human Fetuin-A ELISA



## 11 WARRANTY

This product is warranted to perform as described in its labeling and literature when used in accordance with all instructions. DRG. DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, and in no event shall DRG be liable for consequential damages. Replacement of the product or refund of the purchase price is the exclusive remedy for the purchaser. This warranty gives you specific legal rights and you may have other rights, which vary from state to state.

## 12 REFERENCES / LITERATURE

1. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/Fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. *J Biol Chem.* 1996 Aug 23;271:20789-96.
2. Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, Kaiser S, Blessing M. Cloning and targeted deletion of the mouse Fetuin gene. *J Biol Chem.* 1997 Dec 12;272:31496-503.
3. Mizuno M, Farach-Carson MC, Pinero GJ, Fujisawa R, Brunn JC, Seyer JM, Bousfield GR, Mark MP, Butler WT. Identification of the rat bone 60K acidic glycoprotein as alpha 2HS-glycoprotein. *Bone Miner.* 1991 Apr;13:1-21.
4. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK. Discovery of a high molecular weight complex of calcium, phosphate, Fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. *J Biol Chem.* 2002 Feb 8;277:3926-34.
5. Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahnen-Dechent W, Floege J. Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/Fetuin. *Blood Purif.* 2002;20:473-476.
6. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low Fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. *Lancet.* 2003 Mar 8;361:827-833.
7. Ketteler M, Wanner C, Metzger T, Bongartz P, Westenfeld R, Gladziwa U, Schurgers LJ, Vermeer C, Jahnen-Dechent W, Floege J. Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. *Kidney Int Suppl.* 2003 May:S84-87.
8. Schäfer C, Heiss A, Schwarz A, Ralf Westenfeld R, Ketteler M, Floege J, Müller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/Fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest.* 2003 Aug;112(3):357-66.
9. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M, Nordfors L. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney Int.* 2005 Jun;67(6):2383-92.
10. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. *Nephrol Dial Transplant.* 2005 Aug;20(8):1676-85.
11. Sato H, Kazama JJ, Wada Y, Kuroda T, Narita I, Gejyo F, Gao P, Yamashita H. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. *Intern Med.* 2007;46(20):1685-91. Epub 2007 Oct 15.
12. Lehtinen AB, Burdon KP, Lewis JP, Langefeld CD, Ziegler JT, Rich SS, Register TC, Carr JJ, Freedman BI, Bowden DW. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. *J Clin Endocrinol Metab.* 2007 Jan;92(1):345-52. Epub 2006 Oct 24
13. Lim P, Collet JP, Moutereau S, Guigui N, Mitchell-Heggs L, Loric S, Bernard M, Benhamed S, Montalescot G, Randé JL, Guéret P. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. *Clin Chem.* 2007 Oct;53(10):1835-40. Epub 2007 Aug 16

14. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG; Health ABC Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA. 2008 Jul 9;300(2):182-8.
15. Ix JH, Wassel CL, Bauer DC, Toroian D, Tylavsky FA, Cauley JA, Harris TB, Price PA, Cummings SR, Shlipak MG; for the Health ABC Study. Fetuin-A and Bone Mineral Density in Older Persons: The Health Aging and Body Composition (Health ABC) Study. J Bone Miner Res. 2008 Nov 18.
16. Giulia Bivona, Chiara Bellia, Antonietta Caruso, Daniela Butera, Bruna Lo Sasso, Patrizia Altavilla, Rosa C. Carollo, Gaia Chiarello and Marcello Ciaccio. Low Serum Fetuin A Levels and Cardiovascular Events in End-Stage Renal Disease (ESRD) Patients. Research Journal of Medical Sciences 2 (4): 200-202, 2008
17. Mario Cozzolino, Andrea Galassia, Maria Luisa Biondib, Olivia Turrib, Sergio Papagnic, Nicola Mongellic, Luigi Civitac, Maurizio Gallenia, Diego Brancaccio. Serum Fetuin-A Levels Link Inflammation and Cardiovascular Calcification in Hemodialysis Patients. Am J Nephrol 2006;26:423-429
18. G. Metry, P. Stenvinkel, A. R. Qureshi, J. J. Carrero, M. I. Yilmaz, P. Bárány, S. Snaedal, O. Heimbürger, B. Lindholm and M. E. Suliman Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. European Journal of Clinical Investigation 2008;38(11):804 - 811
19. Doris Hendig, Veronika Schulz, Marius Arndt, Christiane Szliska, Knut Kleesiek, and Christian Goertting. Role of Serum Fetuin-A, a Major Inhibitor of Systemic Calcification, in Pseudoxanthoma Elasticum. Clin Chem 2006;52:227-234
20. G. Marhaug, V. Shah, R. Shroff, H. Varsani, L. R. Wedderburn, C. A. Pilkington and P. A. Brogan. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology 2008 47(7):1031-1037
21. Marcello Ciaccio, et al. Changes in serum fetuin-A and inflammatory markers levels in end-stage renal disease (ESRD): effect of a single session haemodialysis. Clin Chem Lab Med 2008;46:212–214
22. J. J. Carrero, P. Stenvinkel, B. Fellström, A. R. Qureshi, K. Lamb, O. Heimbürger, P. Bárány, K. Radhakrishnan, B. Lindholm, I. Soveri, L. Nordfors & P. G. Shiels. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. Journal of Internal Medicine 2007; 263(3):302 – 312
23. C. Fiore, G. Celotta, G. Politi, L. Di Pino, Z. Castelli, R. Mangiafico, S. Signorelli, P. Pennisi. Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2007;195:110-115
24. Sandro Mazzaferro, Marzia Pasquali, Francesco Pugliese, Giusi Barresi, Iacopo Carbone, Marco Francone, Daniela Sardella, Franco Taggi. Serum Levels of Calcification Inhibition Proteins and Coronary Artery Calcium Score: Comparison between Transplantation and Dialysis. Am J Nephrol 2007;27:75-83.